Skip to content

Ketamine: all studies

Page 136 of 448: studies 1,351 to 1,360 of 4,475, newest first. Back to the ketamine overview

Research

Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial.

BMC Psychiatry May 7, 2024 Ahmad Zolghadriha, Afagh Anjomshoaa, Mohammad Reza Jamshidi et al. 24 citations Retracted

Major depressive disorder (MDD) is the most disabling and burdensome mental disorder, negatively affecting an individual's quality of life and daily functioning. the current study was conducted with the aim of investigating the clinical effects of intravenous ketamine on symptoms of MDD and suicidal ideation. The current randomized clinical trial was carried out on 64 patients diagnosed with...

Exploring effects and experiences of ketamine in group couples therapy

Journal of Psychedelic Studies May 6, 2024 Mark Cornfield, S. Mcbride, Joseph T. la Torre et al. 6 citations

This study contributes to the understanding of the efficacy, safety, and experience of ketamine-assisted therapy. The paper documents how individuals describe the effects of a protocolized and personalized use of ketamine (‘the relational dose’) in the context of group couples therapy based on Imago Relationship Therapy (IRT). Little is known about simultaneously administering ketamine to both...

Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making.

Elife May 3, 2024 Mariann Oemisch, Hyojung Seo

The discovery of rapid-acting antidepressant, ketamine has opened a pathway to a new generation of treatments for depression, and inspired neuroscientific investigation based on a new perspective that non-adaptive changes in the intrinsic excitatory and inhibitory circuitry might underlie the pathophysiology of depression. Nevertheless, it still remains largely unknown how the hypothesized...

DOI: 10.7554/elife.87529 (opens in new tab) Full text (opens in new tab) Nmda receptor Affective memory Negative valence Reinforcement learning +5

Ketamine-induced prevention of SD-associated late infarct progression in experimental ischemia.

Scientific Reports May 3, 2024 A Zdunczyk, L Schumm, S O A Helgers et al. 5 citations

Spreading depolarizations (SDs) occur frequently in patients with malignant hemispheric stroke. In animal-based experiments, SDs have been shown to cause secondary neuronal damage and infarct expansion during the initial period of infarct progression. In contrast, the influence of SDs during the delayed period is not well characterized yet. Here, we analyzed the impact of SDs in the delayed...

DOI: 10.1038/s41598-024-59835-5 (opens in new tab) Full text (opens in new tab) Experimental ischemia Stroke progression Stroke treatment Neuroprotection +3

Ketamine Crisis: Case Report on the Complications of Ketamine Usage and Its Rise in the United States

Research Posters May 2, 2024 Shika Veera, Vajreshwar Shivaprakash

The recreational use of ketamine poses various health risks, including addiction, cognitive impairments, and physical harm. The patient is a 24-year-old female who presented with 30 lbs. unintentional weight loss, generalized weakness, and urinary incontinence over four months. She endorses right upper quadrant and suprapubic pain with occasional gross hematuria. The patient denied recreational...

Ketamine for Postpartum Depression: A Systematic Review

Research Posters May 2, 2024 Jaylyn Thompson, David F Lo, Alexis Foschini et al.

The purpose of this review is to explore perinatal ketamine’s potential for reducing postpartum depression after cesarean section. Articles reviewed from Pubmed, Cochrane, and Web of Science using specific search terms. 8 final papers were used for review after excluding duplicates and irrelevant titles and abstracts. Ketamine showed potential in reducing postpartum depression symptoms post...

Exploring Cultural Competence, Inclusivity, and Diversity in Ketamine Assisted Psychotherapy: A Phenomenological Study.

Journal of Psychoactive Drugs May 2, 2024 Dave Rojas, Diane C Zelman, Alexander O Hauson et al. 2 citations

Black, Indigenous, and People of Color (BIPOC), and other minoritized populations are insufficiently represented in research on therapeutic psychedelics. This research was a phenomenological qualitative exploration of a culturally diverse (Hispanic, African American, Asian, Native American, biracial, or LGBTQIA+) and low-income sample of 15 individuals receiving ketamine-assisted psychotherapy...

Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.

Journal of the American Academy of Child & Adolescent Psychiatry May 2024 Yanling Zhou, Xiaofeng Lan, Chengyu Wang et al.

Suicide is a major cause of death in adolescents with limited treatment options. Ketamine and its enantiomers have shown rapid anti-suicidal effects in adults with major depressive disorder (MDD), but their efficacy in adolescents is unknown. We conducted an active, placebo-controlled trial to determine the safety and efficacy of intravenous esketamine in this population. A total of 54...

A role of gut-brain axis on prophylactic actions of arketamine in male mice exposed to chronic restrain stress.

Pharmacology, Biochemistry, and Behavior May 1, 2024 Li Ma, Akifumi Eguchi, Guilin Liu et al. 11 citations

The gut-brain axis, which includes gut microbiota and microbiome-derived metabolites, might be implicated in depression. We reported the sustained prophylactic effects of a new antidepressant arketamine in chronic restrain stress (CRS) model of depression. In this study, we investigated the role of gut-brain axis on the prophylactic effects of arketamine in the CRS (7 days) model. Pretreatment...

DOI: 10.1016/j.pbb.2024.173736 (opens in new tab) Full text (opens in new tab) Chronic restrain stress Gut microbiota Metabolites Prophylactic effect: resilience +5

Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: The Bio-K multicenter trial.

Psychiatry Research May 1, 2024 Balwinder Singh, Sagar V Parikh, Jennifer L. Vande Voort et al. 18 citations

This nonrandomized, multicenter, open-label clinical trial explored the impact of intravenous (IV) ketamine on cognitive function in adults (n = 74) with treatment-resistant depression (TRD). Patients received three IV ketamine infusions during the acute phase and, if remitted, four additional infusions in the continuation phase (Mayo site). Cognitive assessments using the Repeatable Battery...

DOI: 10.1016/j.psychres.2024.115829 (opens in new tab) Full text (opens in new tab) Neurocognition Open-label study Rbans Ketamine infusion +4